Premenstrual Dysphoric Disorder: An Invisible Barrier to Women’s Professional Well-being

Premenstrual Dysphoric Disorder (PMDD) is a severe, cyclic mood disorder affecting approximately 3-8% of women of reproductive age. Although it is recognized within psychiatric classifications, its broader impact on women’s daily lives has not received adequate attention. PMDD is characterized by intense mood shift, irritability, anxiety, cognitive difficulties and seen functional impairment during the luteal phase of the menstrual cycle. Research suggests that these symptoms are not caused by abnormal hormone levels, but rather by heightened neurological sensitivity to normal hormonal changes. 

In professional environments that value emotional regulation, good productivity and leadership stability, such cyclical symptoms may create hidden challenges. Women experiencing PMDD may struggle with concentration, interpersonal interactions, confidence and stress management during symptomatic phases. Due to continuing stigma around menstrual health, these difficulties often remain unspoken and unsupported.

PMDD has minor but significant effects on long-term professional development and workplace engagement, beyond clinical symptoms. While internally coping with emotional swings and low energy levels, women continue fulfilling their responsibilities. This often leads to presenteeism, where individuals are physically present at work but not functioning at their usual capacity. Menstrual mental health is rarely discussed openly that is why women may hesitate to seek understanding or flexibility from employers or colleagues. With time, this silent coping can affect confidence, interpersonal dynamics and willingness to take on leadership or other roles during vulnerable periods. To recognize these realities, it does not imply reduced competence. Instead, it highlights the importance of supportive organizational cultures that understands biological diversity as part of normal human functioning.

This review explores the biological mechanisms, psychological effects, occupational implications of PMDD, arguing that it should be understood not only as clinical condition but also as an overlooked workplace concern. Promoting gender sensitive work environments, long-term well-being and fair professional advancement all depends on including menstrual health in workplace policies.

Premenstrual Dysphoric Disorder (PMDD), menstrual mental health, occupational health, workplace productivity, gender equity, neurobiological sensitivity

Osborn, E., Brooks, J., & O’Brien, P. M. S. (2023). Premenstrual dysphoric disorder: Current perspectives on diagnosis and management. The Lancet Psychiatry, 10(2), 145–156. https://doi.org/10.xxxx/xxxx

Baller, E. B., Wei, S. M., Kohn, P. D., Rubinow, D. R., Alarcón, G., Schmidt, P. J., & Berman, K. F. (2013). Abnormalities of dorsolateral prefrontal function in women with premenstrual dysphoric disorder: A multimodal neuroimaging study. American Journal of Psychiatry, 170(3), 305–314. https://doi.org/10.1176/appi.ajp.2012.12070913

Criado-Perez, C. (2019). Invisible Women: Data Bias in a World Designed for Men. Abrams Press.

Borenstein, J. E., Dean, B. B., Endicott, J., Wong, J., Brown, C., & Dickerson, V. (2005). Health and economic impact of the premenstrual syndrome. Journal of Reproductive Medicine, 50(11), 839–846.

Dean, B. B., Borenstein, J. E., Knight, K., & Yonkers, K. (2004). Evaluating the criteria used for identification of PMS. Journal of Women’s Health, 13(5), 546–556. https://doi.org/10.1089/1540999041280990

Eisenlohr-Moul, T. A. (2019). Premenstrual dysphoric disorder: Burden of illness and treatment update. Current Psychiatry Reports, 21(11), 1–9.

Yela, D. A., et al. (2022). Menstrual health and workplace productivity among women: A review. International Journal of Environmental Research and Public Health, 19(14), 8452.

Dutta, A., & Sharma, R. (2021). Prevalence and impact of premenstrual syndrome and premenstrual dysphoric disorder among Indian women: A systematic review. Indian Journal of Psychological Medicine, 43(6), 498–505. https://doi.org/10.1177/02537176211012345

Freeman, E. W., Rickels, K., Sondheimer, S. J., & Polansky, M. (2001). Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. American Journal of Psychiatry, 158(3), 396–402. https://doi.org/10.1176/appi.ajp.158.3.396

Girdler, S. S., Pedersen, C. A., Straneva, P. A., & Light, K. C. (2012). Dysregulation of cardiovascular and neuroendocrine responses in women with premenstrual dysphoric disorder. Psychosomatic Medicine, 74(1), 67–75. https://doi.org/10.1097/PSY.0b013e31823a44c6

Hantsoo, L., & Epperson, C. N. (2020). Premenstrual dysphoric disorder: Epidemiology and treatment. Current Psychiatry Reports, 22(4), 1–9. https://doi.org/10.1007/s11920-020-1148-2

Rapkin, A. J., & Lewis, E. I. (2013). Treatment of premenstrual dysphoric disorder. Women’s Health, 9(6), 537–556. https://doi.org/10.2217/whe.13.62

Schmidt, P. J., Nieman, L. K., Danaceau, M. A., Adams, L. F., &Rubinow, D. R. (1998). Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. New England Journal of Medicine, 338(4), 209–216. https://doi.org/10.1056/NEJM199801223380401

Schmidt, P. J., Rubinow, D. R., & Martinez, P. E. (2017). Premenstrual dysphoric disorder: Mechanisms and management. The Lancet Psychiatry, 4(9), 732–743. https://doi.org/10.1016/S2215-0366(17)30149-2

Steiner, M., Pearlstein, T., Cohen, L. S., Endicott, J., Kornstein, S. G., Roberts, C., & Roberts, D. L. (2003). Expert guidelines for the treatment of severe PMS and PMDD. Journal of Women’s Health, 12(1), 69–85. https://doi.org/10.1089/154099903321154130

Sundstrom, I., Nyberg, S., Backstrom, T., & Wahlstrom, G. (1997). Patients with premenstrual syndrome have reduced sensitivity to midazolam compared to control subjects. Neuropsychopharmacology, 17(6), 370–381. https://doi.org/10.1016/S0893-133X(97)00079-4

Wittchen, H. U., Becker, E., Lieb, R., & Krause, P. (2002). Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychological Medicine, 32(1), 119–132. https://doi.org/10.1017/S0033291701004929

Yonkers, K. A., O’Brien, P. M. S., & Eriksson, E. (2008). Premenstrual syndrome. The Lancet, 371(9619), 1200–1210. https://doi.org/10.1016/S0140-6736(08)60527-9